Medplus Healthcare Share Price Falls 3% After Karnataka Store Drug License Suspension

On October 13, 2025, Medplus Healthcare share price (NSE: MEDPLUS) fell sharply, hitting an intra-day low of ₹755.3 on BSE, down 3.6%. At 10:34 AM, the stock was trading at ₹765, down 2.42%, while the BSE Sensex declined 0.39% to 82,178.23. The company’s market capitalisation stands at ₹9,166.43 crore, with a 52-week high of ₹1,052.05 and a low of ₹603.

Reason for the Decline

The selling pressure was triggered after Optival Health Solutions, a subsidiary of Medplus, received a 15-day suspension order for its drug license at a store located on MG Road, Chikkamagalore, Karnataka. 

Other Recent License Suspensions

Earlier, on October 9, 2025, a store in Vizianagaram, Andhra Pradesh, also faced a 7-day suspension. Additionally, select stores in Chhattisgarh and Telangana experienced similar drug license suspensions, indicating a regulatory enforcement wave across multiple states.

About Medplus Healthcare

Medplus is a pharmacy retail brand that operates 4,230 stores across 600 cities in 10 states, including Tamil Nadu, Karnataka, Telangana, Andhra Pradesh, Odisha, West Bengal, Maharashtra, Kerala, Chhattisgarh, and Madhya Pradesh. Its business includes retail and wholesale sales, manufacturing of private label pharmaceutical and wellness products, distribution, and diagnostic centres, leveraging technology to improve supply chain efficiency and customer value.

Also Read: NSE Announces Muhurat Trading 2025 Timings for Diwali, Shifted to Afternoon!

Conclusion

Medplus Healthcare shares fell 3% due to the temporary suspension of drug licenses at select stores, mainly in Karnataka. Despite this, strong operations across 10 states and reaffirmed credit ratings indicate the company remains well-positioned to manage short-term regulatory challenges.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.